Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4A | O75164 | 2/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18117060 | 0.83 | KDM4A (0.51) | PYCR1KDM4AKDM4CKMT2ALMNA | |
| SCHEMBL23640623 | 0.83 | PYCR1 (0.63) | PYCR1HSD17B10KMT2ALMNATMEM97 | |
| SCHEMBL23849355 | 0.83 | KDM4A (0.46) | PYCR1KDM4AKDM4CTMEM97SIGMAR1 | |
| SCHEMBL40675 | 0.82 | KDM4A (0.66) | KDM4AKDM4CKMT2ATMEM97SIGMAR1 | |
| SCHEMBL71846 | 0.80 | HSD17B10 (0.55) | PYCR1HSD17B10KMT2ALMNAALDH1A1 | |
| SCHEMBL12639940 | 0.79 | PYCR1 (0.58) | PYCR1KMT2ALMNASIGMAR1SMN1; SMN2 | |
| SCHEMBL15942946 | 0.79 | SIGMAR1 (0.58) | KDM4AKDM4CKMT2ALMNATMEM97 | |
| SCHEMBL31725230 | 0.77 | PYCR1 (0.59) | PYCR1HSD17B10KMT2ALMNASMN1; SMN2 | |
| SCHEMBL11806886 | 0.77 | LTA4H (0.56) | PYCR1KMT2ATMEM97SIGMAR1SMN1; SMN2 | |
| SCHEMBL12734915 | 0.76 | PYCR1 (0.62) | PYCR1HSD17B10KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| WO-2022023723-A1 | GLP-1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-02-03 | — | — | WO | disclosed |
| US-20220016254-A1 | CONJUGATES OF FUSION PROTEINS OF GLP-1 AND FGF21 | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| WO-2021186166-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021186169-A1 | ORAL GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021139744-A1 | CONJUGATES OF FUSION PROTEINS OF GLP-1 AND FGF21 | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021136223-A1 | FUSION PROTEINS OF GLP-1 AND GDF15 AND CONJUGATES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-07-08 | — | — | WO | disclosed |
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| EP-1863521-B1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2014-05-07 | — | — | EP | disclosed |
| EP-1863839-B1 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2010-08-04 | — | — | EP | disclosed |
| US-20090318353-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2009-12-24 | — | — | US | disclosed |
| US-20090318353-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2009-12-24 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
| WO-2008023050-A1 | ACYLATED EXENDIN-4 COMPOUNDS | NOVO NORDISK A/S (DK) | 2008-02-28 | — | — | WO | disclosed |
| WO-2006097537-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097538-A1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | PYCR1 2422/4885HSD17B10 1994/4885KDM4A 3549/4885 |
| US-20090318353-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | PYCR1 2749/4885HSD17B10 2503/4885KDM4A 652/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | PYCR1 2161/4885HSD17B10 672/4885KDM4A 2933/4885 |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | GLP1R, GIPR, NPY4R | PYCR1 1584/4885HSD17B10 2048/4885KDM4A 1870/4885 |
| US-20220016254-A1 | CONJUGATES OF FUSION PROTEINS OF GLP-1 AND FGF21 | GLP1R, GIPR, FGFR1 | PYCR1 1608/4885HSD17B10 1460/4885KDM4A 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.